seagen
Pfizer is merging with Seagen in a $43 billion acquisition.Seagen was a sought-after target and Pfizer is succeeding where Merck failed, but it paid a premium to do so.Pfizer is expecting the acquisition to add $10 billion in revenue by 2030; early indications suggest analysts are less convinced.If Pfizer is right, this would be the element that was missing from an otherwise attractively priced stock.5 stocks we like better than PfizerQ4 2022 hedge fund letters, conferences and more Find A Qualified Financial AdvisorFinding a qualified financial advisor doesn't have to be hard. SmartAsset's fr...
ValueWalk
Washington (AFP) - US pharmaceutical giant Pfizer announced Monday that it had reached a deal to buy biotech firm Seagen, specializing in innovative cancer treatment, for $43 billion. Pfizer is offering $229 per share in cash, and the companies expect to complete the transaction later this year or in early 2024, they said in a statement. "Pfizer is deploying its financial resources to advance the battle against cancer," said Pfizer CEO Albert Bourla. "Oncology continues to be the largest growth driver in global medicine, and this acquisition will enhance Pfizer's position in this important spa...
AFP
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら